Cytek Biosciences, Inc. (CTKB)
CTKB Stock Price Chart
Explore Cytek Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze CTKB price movements and trends.
CTKB Company Profile
Discover essential business fundamentals and corporate details for Cytek Biosciences, Inc. (CTKB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
23 Jul 2021
Employees
663.00
Website
https://cytekbio.comCEO
Wenbin Jiang
Description
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.
CTKB Financial Timeline
Browse a chronological timeline of Cytek Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.02, while revenue estimate is $48.61m.
Earnings released on 7 May 2026
EPS came in at -$0.12 falling short of the estimated -$0.08 by -50.00%, while revenue for the quarter reached $44.14m , missing expectations by -0.22%.
Earnings released on 26 Feb 2026
EPS came in at -$0.01 surpassing the estimated -$0.02 by +50.00%, while revenue for the quarter reached $62.14m , beating expectations by +8.73%.
Earnings released on 5 Nov 2025
EPS came in at -$0.01 falling short of the estimated $0.01 by -200.00%, while revenue for the quarter reached $52.29m , missing expectations by -11.07%.
Earnings released on 6 Aug 2025
EPS came in at $0.01 surpassing the estimated -$0.02 by +150.00%, while revenue for the quarter reached $45.60m , missing expectations by -1.61%.
Earnings released on 8 May 2025
EPS came in at -$0.09 falling short of the estimated -$0.04 by -125.00%, while revenue for the quarter reached $41.46m , missing expectations by -2.83%.
Earnings released on 27 Feb 2025
EPS came in at $0.07 surpassing the estimated $0.05 by +40.00%, while revenue for the quarter reached $57.48m , missing expectations by -3.21%.
Earnings released on 5 Nov 2024
EPS came in at $0.01 surpassing the estimated $0.00 by +166.67%, while revenue for the quarter reached $51.50m , missing expectations by -15.42%.
Earnings released on 6 Aug 2024
EPS came in at -$0.08 falling short of the estimated -$0.03 by -166.67%, while revenue for the quarter reached $46.62m , missing expectations by -8.05%.
Earnings released on 8 May 2024
EPS came in at -$0.05 matching the estimated -$0.05, while revenue for the quarter reached $44.86m , beating expectations by +2.91%.
Earnings released on 28 Feb 2024
EPS came in at $0.07 surpassing the estimated $0.03 by +133.33%, while revenue for the quarter reached $58.60m , beating expectations by +3.57%.
Earnings released on 7 Nov 2023
EPS came in at $0.01 surpassing the estimated -$0.33 by +103.00%, while revenue for the quarter reached $48.00m , missing expectations by -13.48%.
Earnings released on 8 Aug 2023
EPS came in at $0.01 surpassing the estimated -$0.01 by +200.00%, while revenue for the quarter reached $49.69m , missing expectations by -13.79%.
Earnings released on 9 May 2023
EPS came in at -$0.03 falling short of the estimated -$0.02 by -100.00%, while revenue for the quarter reached $37.09m , missing expectations by -18.88%.
Earnings released on 28 Feb 2023
EPS came in at $0.07 surpassing the estimated $0.05 by +40.00%, while revenue for the quarter reached $164.04m , beating expectations by +247.90%.
Earnings released on 9 Nov 2022
EPS came in at $0.04 surpassing the estimated $0.02 by +100.00%, while revenue for the quarter reached $40.48m , missing expectations by -6.49%.
Earnings released on 10 Aug 2022
EPS came in at $0.03 surpassing the estimated $0.02 by +79.96%, while revenue for the quarter reached $40.16m , beating expectations by +1.34%.
Earnings released on 11 May 2022
EPS came in at $0.01 surpassing the estimated $0.00 by +300.00%, while revenue for the quarter reached $35.06m , beating expectations by +7.86%.
Earnings released on 23 Feb 2022
EPS came in at $0.05 surpassing the estimated $0.04 by +19.99%, while revenue for the quarter reached $38.89m , beating expectations by +6.79%.
Earnings released on 8 Nov 2021
EPS came in at $0.02 falling short of the estimated $0.02 by -14.27%, while revenue for the quarter reached $34.38m , beating expectations by +13.05%.
Earnings released on 3 Sept 2021
EPS came in at $0.02 , while revenue for the quarter reached $30.41m .
Earnings released on 27 Jul 2021
EPS came in at $0.00 , while revenue for the quarter reached $24.27m .
CTKB Stock Performance
Access detailed CTKB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
